Diabetes Mellitus Type 2
Conditions
Keywords
Acipimox, GLP-1, Insulin secretion
Brief summary
Glucagon like peptide 1 is produced in enteroendocrine L cells in the small intestine stimulated by peroral food intake. GLP-1 induces insulin secretion, and analogues are used in the treatment of DM2 (type 2 diabetes mellitus). Recently it was found, that levels of GLP-1 are increased in response to acipimox. The hypothesis is that G protein coupled receptors on enteroendocrine L cells bind acipimox and thereby induce GLP-1 secretion. In a controlled, open, randomized experiment, eight healthy, overweight men will be studied on an intervention day, where they receive acipimox, and on a control day. The study day includes an OGTT (oral glucose tolerance test), blood samples before and after the OGTT and a biopsy from adipose tissue.
Interventions
DRUGAcipimox
P.o. administration of 250 mg acipimox
Sponsors
University of Aarhus
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
20 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
* Adult men * Healthy * BMI 25-35
Exclusion criteria
* Known DM2 * Receiving hypolipidemic drugs
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Levels of GLP-1 in plasma | 9 months |
Secondary
| Measure | Time frame |
|---|---|
| Lipolytic activity in adipose tissue by measuring FFA (free fatty acid) levels | 9 months |
| Insulin sensitivity by measuring blood glucose after an OGTT | 5 months |
Other
| Measure | Time frame |
|---|---|
| Insulin secretion by measuring levels of insulin and c-peptid | 9 months |
| Secretion of the hormones ghrelin, leptin and GIP (gastric inhibitory polypeptide) by measuring hormone levels in plasma | 9 months |
Countries
Denmark
Outcome results
None listed